Clinical Trial Update: A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study [Phase 1, Phase 2]

View source ↗

Summary

A head-to-head prospective comparison of two PET/CT tracers for nasopharyngeal carcinoma has been completed in a single center, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• [68Ga]Ga-FAPI (Gallium-68 labeled fibroblast activation protein inhibitor)
• [68Ga]Ga-TATE (Gallium-68 labeled trans-activating transcriptional activator (TATE) analog tracer)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Tumor Positron-Emission Tomography | Phase 1, Phase 2 | Status: COMPLETED